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Non-standard abbreviations 
CL-K1: collectin kidney 1 
CL-L1: collectin liver 1 
HSA: human serum albumin 
KD: dissociation constant 
MAp: MBL-associated protein 
MASP: MBL-associated serine protease 
MBL: mannan-binding lectin  
NHS: normal human serum 
O/N: over night 
PRM: pattern recognition molecule 
rMBL: recombinant MBL 
RT: room temperature 
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ABSTRACT 
 
The complement system is part of the innate immune system and is involved in recognition and clearance 
of pathogens and altered-self structures The lectin pathway of the complement system is initiated when 
soluble collagen-region containing pattern recognition molecules (PRMs) bind to foreign or altered self-
surfaces. Associated with the collagen stems of these PRMs are three mannan-binding lectin (MBL)-
associated serine proteases (MASPs) and two MBL-associated proteins (MAps). The most studied of the 
PRMs, MBL, is present in serum mainly as trimeric and tetrameric oligomers of the structural subunit. We 
hypothesized that oligomerization of MBL may influence both the potential to bind to microorganisms and 
the interaction with the MASPs and MAps, thus influencing the ability to initiate complement activation. 
When testing binding at 37°C, we found higher binding of tetrameric MBL to Staphylococcus aureus than 
trimeric and dimeric MBL. In serum, we found that tetrameric MBL was the main oligomeric form present 
in complexes with the MASPs and MAp44. Such preference was confirmed using purified forms of 
recombinant MBL (rMBL) oligomers, where tetrameric rMBL interacted stronger with all of the MASPs and 
MAp44, compared to trimeric MBL. As a direct consequence of the weaker interaction with the MASPs, we 
found that trimeric rMBL was inferior to tetrameric rMBL in activating the complement system. Our data 
suggests that the oligomeric state of MBL is crucial both for the binding properties and the effector 
function of MBL.   
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INTRODUCTION 
 
The complement system is involved in recognition and clearance of pathogens and altered-self structures 
(1). It is thus an important and integral part of the innate immune system and deficiencies of the 
complement system can lead to diseases. The complement system may be viewed as a cascade enzymatic 
system composed of multiple serine proteases as well as proteins enhancing or inhibiting these proteases. 
The complement system is divided into three initiating pathways: the lectin, the classical, and the 
alternative pathway. Although different in the initiating processes, the ultimate outcome is to eradicate 
dangerous material such as bacteria, viruses or to remove altered-self to sustain homeostasis (1). A major 
function of the alternative pathway is to potentiate the other pathways, while the lectin and the classical 
pathway actively recognize pathogen-associated molecular patterns via pattern recognition molecules 
(PRMs). The lectin pathway encompasses a number of PRMs including four collectins (mannan-binding 
lectin (MBL), collectin kidney 1 (CL-K1), collectin liver 1 (CL-L1) (2) and heterocomplexes of CL-K1 and CL-L1 
(CL-LK) (3)) and three ficolins (M-, L- and H-ficolin, also known as Ficolin-1, -2 and -3, respectively) (4). All of 
these PRMs interact with three different proteases, originally named MBL-associated serine proteases, 
MASPs (MASP-1, MASP-2 and MASP-3) and two so-called MBL-associated proteins, MAps (MAp44 and 
MAp19) (4). In contrast, the classical system only contains one PRM, the C1q molecule, which together with 
its associated serine proteases C1r and C1s forms the C1 complex (5). 
Clustering of PRM/MASP complexes on ligand surfaces leads to activation of the lectin pathway. Thus the 
zymogen MASP molecules must be positioned close to each other (juxta-positioning) for efficient activation 
to take place (6). Activated, MASP-1 efficiently cleaves and activates MASP-2 (7-9), which then cleaves the 
complement components C4 and C4-bound C2, generating the C3 convertase (C4bC2a). MASP-1 also 
contributes by cleaving C4-bound C2 (10). 
The polypeptide chains of the collectins and ficolins are composed of similar motifs: a short N-terminal 
containing cysteines involved in oligomerization of the polypeptide chain followed by a collagen-like region 
responsible for formation of a collagen-like triple helix providing for MASP/MAp interaction, and finally a C-
terminal ligand recognition domain (carbohydrate recognition domains for the collectins, and fibrinogen-
like domains for the ficolins). For MBL and the ficolins three identical polypeptide chains trimerize into 
structural subunits, which further oligomerizes into higher oligomer (11). CL-LK is an exception as it is 
composed of two different polypeptide chains (CL-K1 and CL-L1) forming the structural subunit and the 
higher oligomers (3).   
 
The dissociation constant (KD) of the single carbohydrate recognition domain of MBL towards a target is in 
the low millimolar region (12), whereas the avidity of the whole molecule for larger patterns of 
carbohydrates is dependent on the degree of oligomerization, reaching low nanomolar KD values for the 
higher oligomers (13, 14). Also the interaction between MBL and the MASPs and MAps might be dependent 
on the oligomerization of MBL. It has previously been suggested that, e.g. the trimeric oligomer of MBL 
interacts mainly with MASP-1 (15, 16), although this is not evident in another study where the same affinity 
was observed for interaction with the trimer and the tetramer (17). 
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Here we investigate how oligomerization influences the ability of MBL to bind to Staphylococcus aureus, 
how oligomerization of MBL influences the interaction with the MASPs and MAps, and how oligomerization 
affect the ability to activate the lectin pathway of the complement system. In contrast to certain previous 
studies, we observe a significant difference between the interactions of trimeric and tetrameric MBL with 
the MASPs and MAps, and as a likely consequence, we also observe a clear difference in activation 
potential. 
 
 
MATERIALS AND METHODS 
 
Buffers and antibodies. TBS was 10 mM Tris-HCl, 140 mM NaCl, 15 mM NaN3, pH 7.4. TBS/Tw was TBS, 
0.05% (v/v) Tween-20. TBS/Ca
2+
 was TBS, 5 mM CaCl2. Calcicum containing running buffer for anion 
exchange chromatography was 10 mM Tris, 5 mM CaCl2, pH 8.5. EDTA running buffer was 10 mM Tris, 50 
mM NaCl, 10 mM EDTA, pH 8.5. PBS was 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, and 8.1 mM Na2HPO4, 
pH 7.4. Blocking buffer was TBS with 1 mg human serum albumin (HSA) per ml. TBS/Tw/Ca
2+
 was TBS/Tw, 5 
mM CaCl2. Dilution buffer for time resolved immune fluorometric assay (TRIFMA) was 10 mM Tris-HCl, 1 M 
NaCl, 5 mM CaCl2, 15 mM NaN3, pH 7.4, containing 1 mg HSA/ml, 0.05% (v/v) Triton X-100 and 100 μg/ml of 
of rat IgG (Lampire), mouse IgG (Lampire), bovine IgG (Lampire) and heat-aggregated human IgG 
(Beriglobulin, CSL Behring; heat-aggregated by incubating at 63
o
C for 30 min, followed by centrifugation at 
3,000g and recovery of the supernatant). Europium buffer was TBS/Tw, 25 μM EDTA. Carbonate coating 
buffer was 15 mM Na2CO3, 35 mM, NaHCO3, 15 mM NaN3, pH 9.6. Elution buffer was 10 mM Tris-HCl, 1 M 
NaCl, 10 mM EDTA, 100 mM GlcNAc (Sigma), 0.05% (v/v) Tween-20, 15 mM NaN3, pH 7.4. Barbital buffer 
was 4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4. SDS-PAGE sample buffer was 30 mM 
Tris-HCL, 10% (v/v) glycerol, 8 M urea, 3% (w/v) SDS, 0.1% (w/v) bromphenol blue, pH 8.9. Western Blotting 
(WB) buffer was TBS/Tw, 1 mM EDTA with 1 mg HSA/ml. HEPES buffer was 10 mM HEPES, 140 mM NaCl, 5 
mM CaCl2, pH 7.4. 
Mouse monoclonal antibody 5F5 reacts with a domain (the CCP1 domain) shared by MASP-1, -3 and 
MAp44  (18). Mouse monoclonal antibody 8B5 reacts specifically with MASP-2 (19). Mouse monoclonal 
antibody 2D5B6 reacts specifically with MAp44 (18) (Hycult Biotech). Rat monoclonal antibody 38:12-3 
reacts specifically with MASP-3 (10) (Hycult Biotech). Mouse/rat monoclonal antibody 4D12H2 reacts 
specifically with MAp19 (20).  
 
The affinity purified rabbit anti-MASP-1 reacts specifically with MASP-1 and was produced by immunization 
with the serine protease (SP) part of MASP-1 as follows. Briefly, the SP domain of MASP-1 was expressed in 
E. coli and purified to homogeneity analogously to the larger catalytic fragment of MASP-1 (21). Rabbits 
were immunized with 400, then 3-times 200 µg doses of MASP-1 SP, and the antiserum was collected. 
Antibodies of the antiserum were purified by protein A chromatography followed by affinity purification on 
a column with the immobilized antigen. 
 
Mouse monoclonal antibody 131-1 (BioPorto) reacts specifically with MBL (21+1).  
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Fractionation of MBL oligomers. rMBL was produced and purified as described previously (22+1). To 
fractionate the product into the different oligomeric forms we first precipitated the protein with 4.5% or 
5.5% (depending on the specific procedure – see below) PEG-6000 in TBS/Tw for 1 hour at room 
temperature (RT) followed by centrifugation at 10,000g for 10 min. The supernatant was diluted in 
calcicum running buffer and oligomers of MBL were fractionated on a MonoQ 5/50GL column using 
calcicum running buffer and applying a linear gradient to 0.5 M NaCl. Dimer and trimer-containing fractions 
were pooled, made 10 mM in EDTA by adding 100
th
 volume of 1 M EDTA and run again on the MonoQ now 
using EDTA running buffer and applying a linear gradient to 0.5 M NaCl. For the preparation of tetrameric 
MBL, the 5.5% PEG-6000 pellet was redissolved and large oligomers precipitated with 4% PEG-6000 as 
above. The supernatant was run on MonoQ under calcium-containing conditions as described above. 
Tetramer-containing fractions were pooled, made 10 mM in EDTA by adding 100
th
 volume of 1 M EDTA and 
fractionated as above in EDTA containing buffer. The oligomeric state of the rMBL in the fractions was 
visualized on silver stained SDS-PAGE gels. The protein concentrations of the rMBL oligomers were 
measured on a Nanodrop 1000 spectrophotometer. 
 
Assay for MBL. Microtiter plate wells were coated with 1 μg monoclonal anti-MBL antibody 93C (23)  in 
PBS. After incubation over night (O/N) at RT, the wells were blocked with blocking buffer, washed thrice 
with TBS/Tw/Ca
2+
, and samples diluted in the dilution buffer were subsequently added. After incubation 
O/N at 4°C, the wells were washed thrice with TBS/Tw/Ca
2+
, and added biotinylated monoclonal anti-MBL 
antibody (biotin-131-1) at 10 ng per ml TBS/Tw. Following incubation for 2 hours at RT, the wells were 
washed and incubated with europium-labelled streptavidin (Perkin Elmer) at 0.1 μg per ml europium 
buffer. After 1 hour of incubation, the wells were washed, added enhancement solution (Perkin Elmer) and 
time-resolved fluorescence was read on a VICTOR5 plate reader (Perkin Elmer).  
 
C4 activation assay. Microtitre plate wells were coated with mannan (Sigma) at 10 μg per ml carbonate 
coating buffer, blocked and washed. rMBL oligomers were diluted in dilution buffer containing MBL 
deficient serum at a final serum concentration of 0.4% (v/v). The samples were incubated on the mannan 
coat O/N at 4°C. After wash, the wells were eluted with 100 μl elution buffer. The eluate was diluted 10 
fold in TBS/Tw and the concentration of rMBL was measured in the MBL assay as described above. In a 
parallel setup the capacity of the MBL/MASP complexes to activate C4 were estimated (24). Instead of 
eluting MBL complexes purified C4 at 2 μg per ml barbital buffer was added to the wells. After incubation 
for 1.5 hours at 37
o
C, the wells were washed and added 1 μg biotin-anti-C4 (Sigma) per ml TBS/Tw/Ca
2+
, 
incubated for 2 hours at RT, washed and developed with europium-labelled streptavidin as above. 
 
rMBL binding to mannan at 4°C and 37°C. rMBL oligomers were diluted to 100 ng/ml in TBS/Tw/Ca
2+
, 
added to mannan coated microtiter wells and incubated O/N at 4
o
C or 30 min, 1 hour, 2 hours, 5 hours or 
O/N at 37 
o
C. After wash, proteins in the wells were eluted as described above and the eluted MBL 
measured in the MBL assay. 
 
Binding of MBL to Staphylococcus aureus. S. aureus (serotype WOOD) was cultured in Todd-Hewitt broth 
O/N at 37°C under 5% CO2. The bacteria were fixed with formaldehyde at a final concentration of 1% (v/v). 
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Residual aldehyde groups were blocked with 0.1 M ethanolamine (pH 9). The bacteria were sedimented 
(2000g, 15 min, 5°C), washed thrice in TBS and stored at 4°C. rMBL oligomers were diluted to 450 ng/ml in 
TBS/Tw/Ca
2+
 containing MBL deficient serum at a final serum concentration of 10% (v/v). One hundred μl of 
diluted rMBL oligomers were added to 10
9
 bacteria and incubated on rotation for 2 hours at 37°C. The 
bacteria were sedimented and MBL in the supernatant was quantified as described above. 
 
Immunoblotting of MBL/MASP complexes. 50 μl of normal human serum (NHS) was diluted with an equal 
volume of dilution buffer and added to microtiter wells coated with 1 μg 5F5 (monoclonal antibody 
reacting with the common CCP1 domain of MASP-1, -3 and MAp44), 8B5 (anti-MASP-2), 2D5B6 (anti-
MAp44), 38:12-3 (anti-MASP-3), 4D12H2 (anti-MAp19), 131-1 (anti-MBL), rabbit anti-MASP-1, normal 
mouse IgG, normal rat IgG or normal rabbit IgG per ml carbonate coating buffer and incubated O/N at 4
o
C. 
After incubation and wash, the bound complexes were eluted consecutively from 23 identical wells in a 
total of 100 μl 50% (v/v) SDS-PAGE sample buffer in TBS. The proteins in the eluates were fractionated by 
SDS-PAGE, blotted onto nitrocellulose (Bio-Rad), the membrane blocked with TBS, 0.1% (v/v) Tween-20, 
washed and incubated with biotin-131-1 (anti-MBL) in WB buffer, followed by streptavidin-HRP (Sigma) in 
WB buffer without NaN3. Blots were developed with Supersignal West Dura extended duration substrate 
(Pierce) and the signal recorded by a CCD camera. 
 
MAp44, MASP-1, MASP-2 and MASP-3 interaction with rMBL oligomers in serum. rMBL oligomers were 
diluted to 500 ng/ml in TBS/Tw/Ca
2+
 containing 100 μg/ml of each of the following (for reduction of 
background): rat IgG, mouse IgG, bovine IgG and heat-aggregated human IgG, and also containing 5% (v/v) 
MBL deficient serum. Samples were incubated for 2 hours at RT and added to microtitre wells coated with 
1 μg/ml 2D5B6 (anti-MAp44), 8B5 (anti-MASP-2), 38:12-3 (anti-MASP-3) or rabbit anti-MASP-1. Following 
incubation O/N at 4
o
C, the wells were washed thrice in TBS/Tw/Ca
2+
 and incubated for 2 hours at RT with 1 
μg/ml biotinylated MAb 93C (anti-MBL) in dilution buffer. The plates were developed as above. Data was 
compared using one-way ANOVA with Tukey’s post hoc test (GraphPad Prism 5.0). 
 
 
RESULTS 
 
MBL oligomers, binding and activation. Using a combination of PEG precipitation and ion exchange 
chromatography we separated rMBL into distinct oligomers (Fig. 1A). In the dimeric MBL preparation (Fig. 
1A, lane 2) we observed doublet bands: a band of approximately 150 kDa, fitting with the theoretical 
weight of 144 kDa for 6 non-modified polypeptide chains of 24 kDa each, and a band with slightly higher 
molecular weight. The two bands may represent variations in post-translational modifications. This was not 
examined any further. Trimeric MBL (Fig. 1A, lane 3) migrated with an apparent weight of ~250 kDa and 
contained only traces of dimer MBL. Tetrameric MBL (Fig. 1A, lane 4) migrated with a higher weight than 
trimeric MBL, but also contained traces of trimeric and pentameric MBL. We were not able to produce pure 
preparations of any higher oligomeric forms. 
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During the above described purification the concentrations of the various MBL oligomers were determined 
by OD280, i.e., the concentration of polypeptide chains. To be able to compare the complement activating 
potential (see below) of the various MBL oligomers on mannan coated microtiter wells it was essential to 
be able to estimate the amount of MBL actually bound in the wells (and not merely express the capacity as 
compared to how much MBL was added to the well). To be able to estimate the concentration bound in 
mannan coated microtiter wells we eluted the bound MBL with buffer containing EDTA and GlcNAc and 
used a solid phase MBL assay based on two anti-MBL antibodies to measure the concentration of MBL in 
the eluate. The assay we used measures the concentration of MBL polypeptide chains independently of the 
oligomerization (Fig. 1B). As previously described, the selection of the monoclonal anti-MBL antibodies 
used is crucial for the equal estimation of the different oligomers (19). 
 
The complement activation potential of the different oligomers was tested on a mannan surface using MBL 
deficient serum as MASP source (Fig. 1C). Interaction with the mannan surface was at 4
o
C O/N in order to 
allow the likely lower avidity interactions of the smaller oligomers with the ligand. At the chosen 
conditions, the amount of dimeric MBL bound to the mannan surface was equivalent to that of the higher 
oligomeric forms (Fig. 1D). On the other hand, when binding was estimated at 37°C, a clear difference was 
seen between the different oligomeric forms, i.e. much lower binding was seen for trimeric and dimeric 
rMBL as compared to tetrameric rMBL (Fig. 1E). This binding was time dependent, reaching a maximum 
signal after approximately 5 hours. At the conditions used here, ensuring quantitatively equivalent binding 
of the various oligomers at the starting point of the C4 deposition assay, much less C4 fragment deposition 
was accomplished by the trimeric MBL compared to the tetrameric MBL. Dimeric MBL was not able to 
procure C4 deposition on the mannan surface (Fig. 1C).  
 
To compare the binding of the various forms of MBL to a physiological relevant surface, we added rMBL 
oligomers to MBL deficient serum and detected the level of MBL binding to S. aureus. As can be seen in Fig. 
1F more tetrameric rMBL bound to the bacteria compared to the less oligomeric forms. Approximately 30% 
of the added tetrameric rMBL was bound, whereas less than 10% of the trimeric rMBL was bound. Dimeric 
rMBL did not bind to the bacteria. 
 
Analysis of MBL/MASP complexes in serum. MBL/MASP (and MBL/MAp) complexes in serum were affinity 
purified on microtiter wells coated with anti-MASP or anti-MAp specific antibodies. The complexes were 
eluted, separated on SDS-PAGE, Western blotted and the blot was developed for MBL. Wells coated with 
anti-MBL bound the three main forms, i.e. trimer, tetramer and higher forms, found in serum (Fig. 2A and 
Fig. 2B, right lane). Remarkably, the results illustrated by the other lanes demonstrate that only miniscule 
amounts of trimeric MBL was present in the eluates from wells coated with anti-MASP-2, anti-MASP-3, 
anti-MAp44 or antibody reacting with the common part of MASP-1/MASP-3/MAp44) (Fig. 2A) or from wells 
coated with anti-MASP-1 (Fig. 2B), indicating that in serum, the trimeric MBL interacts only weakly with all 
of the MASPs and MAp44 as compared to tetrameric and pentameric MBL. Microtiter wells coated with 
normal mouse or rat Ig served as negative controls for our monoclonal mouse (anti-MAp44, anti-MASP-1/-
3/MAp44, anti-MBL) and rat (anti-MASP-2, anti-MASP-3) antibodies (Fig. 2A) and wells coated with normal 
rabbit as control for the rabbit anti-MASP-1 (Fig. 2B). No signals were seen in the negative controls. 
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Formation of MBL/MASP complexes. The ability of dimeric, trimeric and tetrameric rMBL to associate with 
MASPs in MBL deficient serum was tested. The various forms were added to MBL deficient serum and 
subsequently added to microtiter wells coated with specific antibodies. Capturing complexes using 
antibodies recognizing MAp44 (Fig. 3A), MASP-2 (Fig. 3B), MASP-1 (Fig. 3C) or MASP-3 (Fig. 3D) and 
subsequently developing for MBL, showed a clear difference between trimeric and tetrameric rMBL, with 
less complexes of trimeric rMBL being captured (Fig. 3A-D). Neither MAp44 nor the MASPs were found in 
complex with the added dimeric rMBL. 
 
 
DISCUSSION 
 
Variable oligomerization of structural subunits is an inherent feature of all the complement activating PRMs 
of the lectin pathway of complement. The prominent MBL forms found in human serum are trimers and 
tetramers (as also demonstrated in Fig. 2A, right lane), which together comprise about 70% of the serum 
MBL (6, 17). The remaining MBL is mainly present as higher oligomers. It is known for human MBL, that 
higher oligomerization leads to higher ligand avidity (14) and the possibility to associate with more than 
one MASP or MAp dimer (6, 25). In the present report we examine in more detail the effects of 
oligomerization of MBL on ligand interaction, association with MASPs and MAp, and complement 
activation. 
 
We observe that tetrameric rMBL activates complement more efficiently on a mannan surface compared to 
trimeric and dimeric rMBL (Fig. 1C). To ensure equivalent levels of the different rMBL oligomers bound to 
the mannan surface at the initiation of our C4 deposition assay, the incubation was done at 4°C O/N. The 
subsequent incubation with C4 is conducted at 37°C for 1.5 hours. Thus, the initial rMBL surface levels are 
the same but the attachment of the various forms at the following step may be affected, and this may be a 
contributing factor to the lower complement activation seen by dimeric and trimeric rMBL compared to 
tetrameric rMBL (Fig. 1C).  
 
The mannan surface used in the microtiter-well-based assays is a substitute for yeast surfaces. The 
dependence of oligomerization for binding to ligands was also seen when studying whole bacteria, where 
tetrameric rMBL also binds stronger compared to the lower oligomer forms (Fig. 1F). 
 
In MBL assays based on catching MBL on a mannan surface and developing for bound MBL, higher oligomer 
forms are more efficiently measured, which would skew the measurement of the lower forms investigated 
in this study (23). The combination of monoclonal antibodies used in the present study was previously 
found capable of determining not only functional MBL but also the aberrant MBL in persons with MBL 
allotypes associated with MBL deficiency (19). In our study we find that this combination also measure 
different recombinant MBL oligomers with equal efficiency (Fig. 1B). 
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MASPs and MAp form homodimers and both the trimeric and the tetrameric MBL oligomers form 1:1 
complexes with the MASP dimers or the MAp dimers (17). Theoretically, this corresponds to 100% 
occupancy of the four collagen binding sites present in a MASP dimer (26) for tetramic MBL, and 75% for 
trimeric MBL. Intuitively, this suggests a difference in the interaction properties of tetrameric and trimeric 
MBL towards the associated enzymes and proteins. 
 
We observe a clear dependence of oligomerization on the ability of MBL to interact with MASPs. We were 
able to purify MBL/MASP and MBL/MAp44 complexes from NHS using specific antibodies targeting the 
MASPs or MAp44 and visualize the oligomer forms of the bound MBL by eluting the MBL and analysis via 
Western blotting (Fig. 2A and Fig. 2B). Even though trimers constitute a significant proportion of serum 
MBL (~35% (6)), and as seen in eluates from the anti-MBL coated wells, only minimal amounts of complexes 
containing trimeric MBL were purified on MASP or MAp44 specific antibodies. This finding was 
substantiated when adding purified oligomeric forms of rMBL to MBL deficient serum followed by 
detection of the MAp44, MASP-2, MASP-3 or MASP-1 in complex with the added rMBL (Fig. 3A-D). We 
found that significantly less trimeric MBL could be recovered in complex with MAp44, MASP-2, MASP-3 or 
MASP-1 compared to that of tetrameric MBL. Dimeric rMBL did not lead to complexes with MASPs or 
MAp44.  
 
Trimeric and tetrameric MBL purified from human serum were previously shown to interact equally well 
with the MASPs when analyzed by surface plasmon resonance, i.e., measured by interaction of MASP to 
immobilized MBL (17). Also, 
35
S-labeled rat MBP-A binding to coated recombinant CUB1-EGF-CUB2 domains 
of MASP-1 or MASP-2 was equally well inhibited by trimeric and tetrameric MBL-A, but less by dimeric MBL 
(27). In the present report we test the interaction properties in serum which may give results closer to the 
physiological situation. 
  
As an obvious consequence of the observed binding properties, trimeric rMBL was less effective in 
activating the lectin pathway, whereas dimeric was nearly completely incapable of activating (Fig. 1C). This 
contradicts the rat scenario where trimers activates complement similar to tetramers (28), but agrees with 
studies using plasma purified MBL where a preparation of mainly tetrameric MBL activated better than a 
preparation of trimeric and tetrameric MBL (29).  
 
In conclusion, tetrameric MBL seems to be a more effective PRM compared to trimeric MBL, as tetrameric 
MBL not only shows superior binding to carbohydrate patterns, but also interact stronger with the MASPs. 
One is left wondering what might be the purpose of the lower oligomeric forms. Different oligomeric forms 
are also seen for the other recognition molecules of the lectin pathway, e.g. a range of oligomers is seen for 
H-ficolin (30) and CL-LK (3) and two forms of oligomers is seen for L-ficolin (Krarup A, Thiel S, Hansen 
A, Fujita T, Jensenius JC. L-ficolin is a pattern recognition molecule specific for acetyl groups. J Biol 
Chem. 2004;279(46):47513-9). Thus, our conclusions might be relevant for all of the lectin pathway 
recognition molecules. 
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Figure 1. Preparations of different oligomers of MBL and estimation of their binding and complement 
activating efficacy. (A) rMBL was fractionated into distinct oligomeric forms using PEG precipitation and 
anion exchange chromotography. Molecular weight markers are seen in lane 1, dimeric rMBL in lane 2, 
trimeric rMBL in lane 3, and tetrameric rMBL in lane 4. (B) The different oligomers were detected equally 
well based on weight in a sandwich type TRIFMA MBL assay. Representative of two individual experiments. 
(C) Activation potential of the oligomeric MBL forms shows that tetrameric rMBL activates complement 
stronger than the lower oligomeric forms. The amount of MBL eluted (i.e. the MBL that had actually bound 
on the mannan) from the wells is shown on the x-axis and the signal from C4b deposited in the 
corresponding wells are on the y-axis. Representative of two individual experiments. (D) The different 
oligomeric rMBL forms bound equally well to mannan at 4°C
 
O/N. Mean and SD of three experiments. (E) At 
37°C  rMBL binding to mannan is dependent on oligomerization and time of incubation in the mannan-
coated wells (time given on x-axis). Mean and SEM of two experiments. (F) Binding of the MBL oligomers to 
S. aureaus. The MBL oligomers were added to MBL deficient serum and the amount of MBL bound at 37°C
 
 
to the bacteria were analysed. Mean and SEM of two experiments. 
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Figure 2. MBL/MASP or MBL/MAp complexes affinity purified from serum. Microtiter wells coated with 
anti-MASP or anti-MAp antibodies were incubated with serum. After wash any bound MBL/MASP or 
MBL/MAp complexes were eluted and examined by Western blotting developed with anti-MBL antibody. 
(A) Complexes were purified on anti-MAp44, anti-MASP-2, anti-MASP-1/-3/MAp44 (targeting the CCP1 
domain in common for MASP-1, MASP-3 and MAp44) and anti-MASP-3. Normal mouse and rat IgG coats 
served as negative controls. Eluate from wells coated with anti-MBL antibody (right hand side of the blot) 
show the total of MBL oligomers present in the serum. As compared to the anti-MBL coated wells no 
complexes containing trimeric MBL were eluted from wells coated with the anti-MASP and anti-MAp 
antibodies. Representative of two individual experiments using serum and one experiment using re-
calcified plasma. (B) Complexes were purified on wells coated with rabbit anti-MASP-1 and rabbit IgG coat 
served as negative control. The signal from anti-MBL coats are shown on the right hand side of the blot. As 
compared to the anti-MBL coated wells no complexes containing trimeric MBL were eluted from wells 
coated with the anti-MASP-1 antibody. Representative of two individual experiments using serum. 
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Figure 3. Tetrameric rMBL binds more MASPs and MAp. (A-D) Oligomeric forms of rMBL were added to 
MBL deficient serum. The formed complexes were caught in wells coated with anti-MAp44 (A), anti-MASP-
2 (B), anti-MASP-1 (C) or anti-MASP-3 (D) and developed with anti-MBL antibody. For comparison, the 
signal obtained with the tetramer rMBL is set to 100%. Data are shown as means with SD of three separate 
experiments. Data was analysed using one-way ANOVA with Tukey’s post hoc test. ** p <0.01, *** p 
<0.001.  
 
 
 
 
